Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.

Autor: Stroot IAS; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, the Netherlands. Electronic address: i.a.s.stroot@umcg.nl., Bart J; University of Groningen, University Medical Center Groningen, Department of Pathology, Groningen, the Netherlands., Hollema H; University of Groningen, University Medical Center Groningen, Department of Pathology, Groningen, the Netherlands., Jalving M; University of Groningen, University Medical Center Groningen, Department of Medical Oncology, Groningen, the Netherlands., Wagner MM; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands., Yigit R; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands., van Doorn HC; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Gynecologic Oncology, Rotterdam, the Netherlands., de Hullu JA; Radboud University Medical Center, Department of Obstetrics and Gynecology, Nijmegen, the Netherlands., Gaarenstroom KN; Leiden University Medical Center, Department of Obstetrics and Gynecology, Leiden, the Netherlands., van Beurden M; Antoni van Leeuwenhoek, Department of Gynecology, Amsterdam, the Netherlands., van Lonkhuijzen LRCW; Amsterdam University Medical Center-Center for Gynecological Oncology Amsterdam, Department of Gynecologic Oncology, Amsterdam, the Netherlands., Slangen BFM; Maastricht University Medical Center, Department of Gynecology, Maastricht, the Netherlands., Zweemer RP; University Medical Center Utrecht, Department of Gynecologic Oncology, Utrecht, the Netherlands., Gómez García EB; University Medical Center Maastricht, Department of Clinical Genetics, Maastricht, the Netherlands., Ausems MGEM; University Medical Center Utrecht, Department of Genetics, Division Laboratories, Pharmacy and Biomedical Genetics, Utrecht, the Netherlands., Boere IA; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Medical Oncology, Rotterdam, the Netherlands., van Hest LP; Amsterdam UMC, Location Vrije Universiteit Amsterdam, Department of Human Genetics, Amsterdam, the Netherlands., Duijkers FAM; Amsterdam UMC, University of Amsterdam, Department of Human Genetics, Amsterdam, the Netherlands., van Asperen CJ; Leiden University Medical Center, Department of Human Genetics & Department of Pathology, Leiden, the Netherlands., Schmidt MK; Leiden University Medical Center, Department of Human Genetics & Department of Pathology, Leiden, the Netherlands; Netherlands Cancer Institute, Department of Epidemiology, Amsterdam, the Netherlands; Netherlands Cancer Institute, Division of Molecular Pathology, Amsterdam, the Netherlands., Wevers MR; Radboud University Medical Center, Department of Clinical Genetics, Nijmegen, the Netherlands., Ruijs MWG; Netherlands Cancer Institute, Department of Clinical Genetics, Amsterdam, the Netherlands., Devilee P; Leiden University Medical Center, Department of Human Genetics & Department of Pathology, Leiden, the Netherlands., Collée JM; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Clinical Genetics, Rotterdam, the Netherlands., Hebon Investigators; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Coordinating Center: Netherlands Cancer Institute, Amsterdam, the Netherlands., de Bock GH; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, the Netherlands., Mourits MJE; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2024 Aug; Vol. 187, pp. 198-203. Date of Electronic Publication: 2024 May 24.

Symptomatic Lymphocele After Robot-Assisted Pelvic Lymphadenectomy as Part of the Primary Surgical Treatment for Cervical and Endometrial Cancer: A Retrospective Cohort Study.

Autor: de Jong A; Department of Gynecologic Oncology (Jong, Jansen, Drs. Baeten, Hoogendam, Jürgenliemk-Schulz, Zweemer, and Gerestein), University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Baeten IGT; Department of Gynecologic Oncology (Jong, Jansen, Drs. Baeten, Hoogendam, Jürgenliemk-Schulz, Zweemer, and Gerestein), University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Jansen A; Department of Gynecologic Oncology (Jong, Jansen, Drs. Baeten, Hoogendam, Jürgenliemk-Schulz, Zweemer, and Gerestein), University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Hoogendam JP; Department of Gynecologic Oncology (Jong, Jansen, Drs. Baeten, Hoogendam, Jürgenliemk-Schulz, Zweemer, and Gerestein), University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Jürgenliemk-Schulz IM; Department of Gynecologic Oncology (Jong, Jansen, Drs. Baeten, Hoogendam, Jürgenliemk-Schulz, Zweemer, and Gerestein), University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Department of Radiation Oncology (Dr. Jürgenliemk-Schulz), University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Zweemer RP; Department of Gynecologic Oncology (Jong, Jansen, Drs. Baeten, Hoogendam, Jürgenliemk-Schulz, Zweemer, and Gerestein), University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Gerestein CG; Department of Gynecologic Oncology (Jong, Jansen, Drs. Baeten, Hoogendam, Jürgenliemk-Schulz, Zweemer, and Gerestein), University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. Electronic address: C.G.Gerestein-2@umcutrecht.nl.

Publikováno v: Journal of minimally invasive gynecology [J Minim Invasive Gynecol] 2024 Mar; Vol. 31 (3), pp. 243-249.e2. Date of Electronic Publication: 2024 Jan 01.

Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study.

Autor: Schuurman TN; Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, location Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, location Amsterdam University Medical Center, Amsterdam, Netherlands., Schaafsma M; Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, location Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Pathology, Amsterdam University Medical Center, location VU University Medical Center, Amsterdam, Netherlands; Department of Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands., To KH; Faculty of Medicine, VU Amsterdam, Amsterdam, Netherlands., Verhoef VMJ; Department of Obstetrics and Gynecology, Maxima Medical Center, Eindhoven, Netherlands., Sikorska K; Department of Biostatistics, Netherlands Cancer Institute, Amsterdam, Netherlands., Siebers AG; Palga, the Dutch Nationwide Pathology Databank, Houten, Netherlands., Wenzel HHB; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands., Bleeker MCG; Department of Pathology, Amsterdam University Medical Center, location VU University Medical Center, Amsterdam, Netherlands; Department of Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands., Roes EM; Department of Obstetrics and Gynecology, Erasmus Medical Center, Rotterdam, Netherlands., Zweemer RP; Department of Gynecologic Oncology, University Medical Center Utrecht, Utrecht, Netherlands., de Vos van Steenwijk PJ; Department of Obstetrics and Gynecology, Maastricht University Medical Center and GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, Netherlands., Yigit R; Department of Obstetrics and Gynecology, University Medical Center Groningen, Groningen, Netherlands., Beltman JJ; Department of Gynecology, Leiden University Medical Center, Leiden, Netherlands., Zusterzeel PLM; Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, Netherlands., Lok CAR; Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, location Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, Netherlands., Bekkers RLM; Department of Obstetrics and Gynecology, Maastricht University Medical Center and GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, Netherlands; Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, Netherlands; Department of Obstetrics and Gynecology, Catharina Hospital, Eindhoven, Netherlands., Mom CH; Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, location Amsterdam University Medical Center, Amsterdam, Netherlands., van Trommel NE; Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, location Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, Netherlands. Electronic address: n.v.trommel@nki.nl.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2023 Dec; Vol. 24 (12), pp. 1349-1358. Date of Electronic Publication: 2023 Nov 09.

Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Patient Characteristics, Treatment, and Outcome-A Systematic Review.

Autor: Wens FSPL; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands., Hulsker CCC; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands., Fiocco M; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.; Mathematical Institute, Leiden University, 2311 EZ Leiden, The Netherlands.; Biomedical Data Science Department, Section Medical Statistics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Zsiros J; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands., Smetsers SE; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands., de Krijger RR; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.; Department of Pathology, University Medical Center Utrecht, 3584 CG Utrecht, The Netherlands., van der Steeg AFW; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands., Zweemer RP; Department of Gynecologic Oncology, Division of Imaging and Oncology, University Medical Center Utrecht, 3584 CG Utrecht, The Netherlands., Baas IO; Department of Medical Oncology, University Medical Center Utrecht, 3584 CG Utrecht, The Netherlands., Roes EM; Department of Gynecologic Oncology, Erasmus Medical Center Cancer Institute, 3015 GD Rotterdam, The Netherlands., Looijenga LHJ; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands., Gerestein CG; Department of Gynecologic Oncology, Division of Imaging and Oncology, University Medical Center Utrecht, 3584 CG Utrecht, The Netherlands., Mavinkurve-Groothuis AMC; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Publikováno v: Cancers [Cancers (Basel)] 2023 Jul 26; Vol. 15 (15). Date of Electronic Publication: 2023 Jul 26.

High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors.

Autor: Stroot IAS; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.; Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Brouwer J; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Bart J; Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Hollema H; Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Stommel-Jenner DJ; Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Wagner MM; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., van Doorn HC; Department of Gynecologic Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., de Hullu JA; Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands., Gaarenstroom KN; Department of Obstetrics and Gynecology, Leiden University Medical Center, Leiden, the Netherlands., Beurden M; Department of Gynecology, Antoni van Leeuwenhoek, Amsterdam, the Netherlands., van Lonkhuijzen LRCW; Department of Gynecologic Oncology, Amsterdam University Medical Center-Center for Gynecological Oncology Amsterdam, Amsterdam, the Netherlands., Slangen BFM; Department of Gynecology, Maastricht University Medical Center, Maastricht, the Netherlands., Zweemer RP; Department of Gynecologic Oncology, University Medical Center Utrecht, Utrecht, the Netherlands., Gómez Garcia EB; Department of Clinical Genetics, University Medical Center Maastricht, Maastricht, the Netherlands., Ausems MGEM; Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands., Boere IA; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., van Engelen K; Department of Human Genetics, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., van Asperen CJ; Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands., Schmidt MK; Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands.; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Wevers MR; Department of Clinical Genetics, Radboud University Medical Center, Nijmegen, the Netherlands., de Bock GH; Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Mourits MJE; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Coordinating Center: Netherlands Cancer Institute, Amsterdam, the Netherlands.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 May 10; Vol. 41 (14), pp. 2523-2535. Date of Electronic Publication: 2023 Feb 21.